In their post hoc exploratory analysis, Bang et al. [81] reported that compared with the placebo, durvalumab affords significant improvements in PFS and OS in patients with a PD-L1+ tumor rate of > 1%; however, such considerable improvement was not observed in patients with a PD-L1+ tumor rate of < 1%. This evidence concerns the gene CD274 and neoplasm.